Rakhee Vaidya, MBBS
- Clinical Associate Professor, Hematology and Oncology
Rakhee Vaidya, MBBS
Research Interests
- Diffuse Large B-Cell Lymphoma
- Double Hit Lymphoma
- Non-Hodgkin Lymphoma
- CAR-T
- Bispecific Antibodies
- Education
- MBBS, Topiwala National Medical College, 2007
- Residency
- Internal Medicine, Western Reserve Care System, 2009
- Internal Medicine, Mayo Clinic, 2011
- Hematology / Oncology, Mayo Clinic, 2014
- Board Certifications
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Medical Oncology
- Positions
- Clinical Associate Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation. Voorhees TJ, Kannan KK, Galeotti J, Grover N, Vaidya R, Moore DT, Montgomery ND, Beaven AW, Dittus C. Leuk Lymphoma. 2021 01; 62(1):86-94.
- Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Haematologica. 2018 11; 103(11):1899-1907.
- Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Leuk. Lymphoma. 2018 08; 59(8):1871-1877.
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):76-81.
- Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, Tefferi A. Am. J. Hematol. 2012 Nov; 87(11):1003-5.